Abbott India Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Abbott India Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 25.0 times. Higher than 98% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 34.4 times by its yearly operating cash. Higher than 88% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹85Over the last 3 years, every ₹100 of reported profit came with ₹85 of operating cash.
Lower than 69% of Healthcare companies in India.
Self-Funding Ratio
25.0×Over the last 3 years its own operating cash covered its investment spending (capex) 25.0 times.
Higher than 98% of Healthcare companies in India.
Cash Locked Ratio
₹2For every ₹100 of sales, ₹2 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹0 tied up three years earlier.
Less money tied up than 86% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹38Sales grew 30% in 3 years; of every extra ₹100 of sales, ₹38 became extra profit.
Higher than 85% of Healthcare companies in India.
Asset Productivity Ratio
+30% / +43%In 3 years sales changed by +30% while total assets changed by +43%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
34.4×Debt due within a year is covered 34.4 times by its yearly operating cash.
Higher than 88% of Healthcare companies in India.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Higher than 78% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 86% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 87% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Abbott India Limited owes ₹0.27 for every ₹1 it owns. Net profit rose 10% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
32.9Investors pay ₹32.9 for every ₹1 of Abbott India Limited's yearly profit, lower than 58% of Healthcare companies in India.
P/B ratio
11.14The share price is 11.14 times Abbott India Limited's book value per share, higher than 85% of Healthcare companies in India.
Market cap
₹53,187 CrThe total market value of all of Abbott India Limited's shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹4,774 CrWhat Abbott India Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹2,247Net worth divided by the number of shares. The share price of ₹25,030 is 11.1 times this, which is the P/B above.
Return on equity (ROE)
33.8%Abbott India Limited earned 33.8% on its shareholders' money over the last year, higher than 94% of Healthcare companies in India.
Owes vs Owns
0.27×Abbott India Limited owes ₹0.27 for every ₹1 it owns (low), lower than 71% of Healthcare companies in India.
Dividend yield
2.02%Abbott India Limited pays 2.02% of its share price as dividends a year, higher than 93% of dividend-paying Healthcare companies in India.
Revenue growth
+8%Revenue rose 8% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
+10%Net profit rose 10% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Profit margin
22.4%Abbott India Limited keeps ₹22 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from Abbott India Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
73.0×Abbott India Limited's operating profit covered its interest costs 73.0 times in the year to Mar 2026.
Cash vs debt
Net cashAbbott India Limited held ₹2,060 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Abbott India Limited's P/E ratio?
Investors pay ₹32.9 for every ₹1 of Abbott India Limited's yearly profit, lower than 58% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Abbott India Limited: ₹53,187 Cr ÷ ₹4,774 Cr (31 Mar 2026) = 11.1.
What is Abbott India Limited's return on equity?
Abbott India Limited earned 33.8% on its shareholders' money over the last year, higher than 94% of Healthcare companies in India.
How much does Abbott India Limited owe compared with what it owns?
Abbott India Limited owes ₹0.27 for every ₹1 it owns (low), lower than 71% of Healthcare companies in India.
Does Abbott India Limited pay a dividend?
Yes. Abbott India Limited pays 2.02% of its share price as dividends a year, higher than 93% of dividend-paying Healthcare companies in India.
Is Abbott India Limited's revenue growing?
Revenue rose 8% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.